Washington, DC’s Secret Weapon for RSV Surveillance
The Washington, DC Public Health Laboratory's Next-Generation Sequencing Core is developing an RSV surveillance system to identify circulating strains and their impact on vulnerable populations. Led by Dr. Eric Vaughn, the team aims to understand the molecular aspects of RSV and other pathogens affecting DC's residents, commuters, and tourists.
The core is using the Illumina Microbial Amplicon Prep (IMAP) kit to simplify RSV sequencing. Their preliminary findings suggest possible distinctions between demographics affected by RSV-A and RSV-B strains. The project will expand during the upcoming respiratory illness season, analyzing more samples to create a real-time picture of RSV's impact on different population groups in the district.
This surveillance system will help the DC Department of Health in prevention and outreach services, potentially guiding targeted interventions based on the specific RSV strains affecting different demographics.
Il Centro di Sequenziamento di Nuova Generazione del Laboratorio di Salute Pubblica di Washington, DC sta sviluppando un sistema di sorveglianza per il RSV per identificare le ceppi circolanti e il loro impatto sulle popolazioni vulnerabili. Guidato dal Dr. Eric Vaughn, il team mira a comprendere gli aspetti molecolari del RSV e di altri patogeni che colpiscono i residenti, i pendolari e i turisti di Washington, DC.
Il centro sta utilizzando il kit Illumina Microbial Amplicon Prep (IMAP) per semplificare la sequenziazione del RSV. I loro risultati preliminari suggeriscono possibili distinzioni tra le demografie colpite dai ceppi RSV-A e RSV-B. Il progetto si espanderà durante la prossima stagione delle malattie respiratorie, analizzando un maggior numero di campioni per creare un quadro in tempo reale dell'impatto del RSV su diversi gruppi popolazionali nel distretto.
Questo sistema di sorveglianza aiuterà il Dipartimento della Salute di DC nei servizi di prevenzione e sensibilizzazione, potenzialmente guidando interventi mirati basati sui ceppi specifici di RSV che colpiscono diverse demografie.
El Centro de Secuenciación de Nueva Generación del Laboratorio de Salud Pública de Washington, DC está desarrollando un sistema de vigilancia para el RSV para identificar las cepas circulantes y su impacto en las poblaciones vulnerables. Dirigido por el Dr. Eric Vaughn, el equipo busca comprender los aspectos moleculares del RSV y otros patógenos que afectan a los residentes, trabajadores y turistas de DC.
El centro está utilizando el kit Illumina Microbial Amplicon Prep (IMAP) para simplificar la secuenciación del RSV. Sus hallazgos preliminares sugieren posibles distinciones entre las demografías afectadas por las cepas RSV-A y RSV-B. El proyecto se expandirá durante la próxima temporada de enfermedades respiratorias, analizando más muestras para crear una imagen en tiempo real del impacto del RSV en diferentes grupos poblacionales en el distrito.
Este sistema de vigilancia ayudará al Departamento de Salud de DC en servicios de prevención y divulgación, potencialmente guiando intervenciones específicas según las cepas de RSV que afectan a diferentes demografías.
워싱턴 DC 공공 건강 연구소의 차세대 염기서열 분석(NGS) 센터에서는 취약한 인구에 미치는 영향을 파악하기 위해 RSV 감시 시스템을 개발하고 있습니다. 에릭 본 박사가 이끄는 팀은 DC의 거주자, 통근자 및 관광객에게 영향을 미치는 RSV 및 기타 병원체의 분자적 측면을 이해하는 것을 목표로 합니다.
이 센터는 RSV 염기서열 분석을 단순화하기 위해 Illumina Microbial Amplicon Prep (IMAP) 키트를 사용하고 있습니다. 그들의 초기 결과는 RSV-A와 RSV-B 균주에 영향을 받는 인구 집단 간의 가능성 있는 구분을 시사합니다. 이 프로젝트는 다음 호흡기 질환 시즌 동안 확대되어, 해당 지역 내 다양한 인구 집단에 대한 RSV의 영향을 실시간으로 분석하기 위해 더 많은 샘플을 분석할 것입니다.
이 감시 시스템은 DC 보건 부서에서 예방 및 홍보 서비스에 도움을 줘, 다양한 인구 집단에 영향을 미치는 특정 RSV 균주에 따라 목표 지향적인 개입을 안내할 수 있습니다.
Le Centre de Séquençage de Nouvelle Génération du Laboratoire de Santé Publique de Washington, DC développe un système de surveillance du RSV pour identifier les souches circulantes et leur impact sur les populations vulnérables. Dirigée par le Dr Eric Vaughn, l'équipe vise à comprendre les aspects moléculaires du RSV et d'autres pathogènes affectant les résidents, les navetteurs et les touristes de DC.
Le centre utilise le kit Illumina Microbial Amplicon Prep (IMAP) pour simplifier le séquençage du RSV. Leurs premières constatations suggèrent des distinctions possibles entre les démographies touchées par les souches RSV-A et RSV-B. Le projet s'élargira durant la prochaine saison des maladies respiratoires, en analysant plus d'échantillons pour créer une image en temps réel de l'impact du RSV sur différents groupes de population dans le district.
Ce système de surveillance aidera le Département de la Santé de DC dans les services de prévention et de sensibilisation, guidant potentiellement des interventions ciblées basées sur les souches spécifiques de RSV touchant différentes démographies.
Der Next-Generation-Sequencing-Kern des öffentlichen Gesundheitslabors von Washington, DC entwickelt ein RSV-Überwachungssystem, um zirkulierende Stämme und deren Auswirkungen auf gefährdete Bevölkerungsgruppen zu identifizieren. Unter der Leitung von Dr. Eric Vaughn hat das Team das Ziel, die molekularen Aspekte von RSV und anderen Pathogenen, die die Bewohner, Pendler und Touristen von DC betreffen, zu verstehen.
Der Kern verwendet das Illumina Microbial Amplicon Prep (IMAP)-Kit, um die RSV-Sequenzierung zu vereinfachen. Vorläufige Ergebnisse deuten darauf hin, dass es mögliche Unterschiede zwischen den von den RSV-A- und RSV-B-Stämmen betroffenen Demografien gibt. Das Projekt wird während der kommenden Atemwegserkrankungssaison ausgeweitet, indem mehr Proben analysiert werden, um ein Echtzeitbild der Auswirkungen von RSV auf verschiedene Bevölkerungsgruppen im Bezirk zu erstellen.
Dieses Überwachungssystem wird dem Gesundheitsministerium von DC bei Präventions- und Aufklärungsdiensten helfen und könnte gezielte Interventionen auf der Grundlage der spezifischen RSV-Stämme, die verschiedene Demografien betreffen, anleiten.
- Development of a robust RSV surveillance system for Washington, DC
- Utilization of Illumina's IMAP kit simplifies RSV sequencing process
- Potential for targeted public health interventions based on strain-specific data
- None.
NORTHAMPTON, MA / ACCESSWIRE / October 1, 2024 / Illumina
The Illumina Microbial Amplicon Prep simplifies a public health laboratory's efforts to track the virus
Originally published on Illumina News Center
The Next-Generation Sequencing Core in the Washington, DC, Public Health Laboratory (PHL) has a critical job: pathogen surveillance for the nation's capital. A team of scientists is trying to understand the molecular underpinnings that drive foodborne illnesses, COVID-19, respiratory syncytial virus (RSV), and other diseases threatening more than one million combined residents and commuters in the District of Columbia (which also welcomed a record 25.95 million tourists last year).
This year, the core has been working closely alongside multiple laboratories within the PHL to determine exactly what kinds of RSV they're dealing with.
"We're not sure of the type of RSV that is predominately circulating," says Eric Vaughn, DrPH, who runs the NGS Core. "We're trying to develop a surveillance system that can identify what strains are impacting our most vulnerable populations."
RSV generally causes mild, cold-like symptoms; however, it can be particularly dangerous for newborns and seniors. The virus has two major strains-RSV-A and RSV-B-as well as several sub-lineages. Vaughn and his colleagues are working to understand what's out in the community and whether it poses a significant danger.
What particular type of RSV is present in different demographics of the district? "If it's B, for example, what type of B?" Vaughn asks. "What are the differences between pediatric and adult cases? If there's a dangerous strain in a particular demographic, does it have a common source?"
Creating a surveillance system
The NGS Core spent last winter developing robust RSV sequencing protocols. All isolates were tested at the PHL for confirmation before being received in the sequencing laboratory for additional testing. During the upcoming respiratory illness season, they will receive more samples from a variety of population groups; this will help them paint a realistic and real-time picture about exactly how the different strains are affecting the district. This work will help them establish and fine-tune an RSV surveillance system, and enable the laboratory's goal to collaborate with the DC Department of Health (a separate entity from the PHL) to get the word out to the community.
Although the team didn't form any strong conclusions during this preliminary period, they analyzed enough samples to get the system going, and they're starting to see a possible distinction between demographics and individuals with RSV-A and those with RSV-B.
"We wanted to establish the testing process, so we can be sure we're accurately differentiating between A and B," Vaughn says. "Once we go into the respiratory season this winter, we hope to get more samples in real time and, hopefully, start forming more solid conclusions."
Essential IMAP
The Illumina Microbial Amplicon Prep (IMAP) kit has been an effective tool to simplify RSV sequencing for the NGS Core. The group didn't have to spend time, or precious patient samples, vetting multiple kits. IMAP offered the products and services that the group needed.
While the project is in its early stages, the NGS Core is intrigued by how the results from the adult and the pediatric samples differ. "The majority of the samples fell into separate groups based on demographics," says Vaughn. "It's pretty eye-opening on what is occurring in the population and could guide DC Health in prevention and outreach services."
View additional multimedia and more ESG storytelling from Illumina on 3blmedia.com.
Contact Info:
Spokesperson: Illumina
Website: https://www.3blmedia.com/profiles/illumina
Email: info@3blmedia.com
SOURCE: Illumina
View the original press release on accesswire.com
FAQ
What is the purpose of the RSV surveillance system being developed in Washington, DC?
How is Illumina (ILMN) technology being used in the Washington, DC RSV surveillance project?
What are the initial findings of the RSV surveillance project in Washington, DC?
When will the Washington, DC RSV surveillance project expand its sample collection?
